ProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results

ProKidney (NASDAQ:PROK) announced its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03), Zacks reports. The business had revenue of $0.08 million for the quarter.

ProKidney Stock Performance

PROK opened at $0.97 on Wednesday. ProKidney has a fifty-two week low of $0.94 and a fifty-two week high of $4.44. The stock has a market capitalization of $282.80 million, a price-to-earnings ratio of -1.76 and a beta of 1.38. The company has a fifty day moving average of $1.45 and a two-hundred day moving average of $1.75.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.